Skip to content
Disclosery

Essex Woodlands Management, Inc.

Follow

13F filer, CIK 1542339, THE WOODLANDS, TX

Essex Woodlands Management, Inc. reported $346,675,640 across 6 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000908834-25-000169

Period
2025-03-31
Reported value
$347M
Holdings
6
Top 10 weight
100%
New
1
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VEROnew+99,021$276K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
REVANCE THERAPEUTICS INCexited-457,085-$1.39M
VENUS CONCEPT INCexited-1,089,190-$414K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0000908834-25-000169, largest first. % of portfolio is the value over $346,675,640, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MDXGMIMEDX GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 28,195,249 shares; 2024Q4: 28,195,249 shares; 2025Q1: 28,195,249 shares 28,195,249$214M61.81%0Timeline
BVSBIOVENTUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 13,021,324 shares; 2024Q4: 13,021,324 shares; 2025Q1: 13,021,324 shares 13,021,324$119M34.37%0Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,551,521 shares; 2024Q4: 1,169,857 shares; 2025Q1: 1,169,857 shares 1,169,857$6.34M1.83%0Timeline
TELATELA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,110,709 shares; 2024Q4: 4,110,709 shares; 2025Q1: 4,110,709 shares 4,110,709$5.02M1.45%0Timeline
MNOVMEDICINOVA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,105,941 shares; 2024Q4: 1,105,941 shares; 2025Q1: 1,105,941 shares 1,105,941$1.61M0.47%0Timeline
VEROVENUS CONCEPT INC COM PAR $0.0Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 99,021 shares 99,021$276K0.08%newTimeline

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
REVANCE THERAPEUTICS INCREVANCE THERAPEUTICS INC457,085$1.39Mshares
VENUS CONCEPT INCVENUS CONCEPT INC1,089,190$414Kshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000908834-25-000169 base2025-05-13acceptance time not in the bulk data set